CSL Limited
ASX:CSL.AX
Sector
Industries
Location
Market Cap
USD 68.89 B
Share Price
USD 141.96
Avg Daily Volume
813,851
Change (1 day)
Change (1 year)
Change (YTD)
Key Data
Company Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Frequently Asked Questions
-
Where is CSL Limited headquartered?
CSL Limited (ASX: CSL.AX) is headquartered at 45 Poplar Road.
-
When was CSL Limited's IPO Date?
CSL Limited (ASX: CSL.AX) had its IPO on June 01, 1994.
-
Who is CSL Limited's CEO?
CSL Limited (ASX: CSL.AX) is led by CEO Paul F. McKenzie.
-
In what sector and industries is CSL Limited active?
CSL Limited (ASX: CSL.AX) is active in the Health Care sector and operates in the following industries: Biotechnology, Pharmaceuticals, Vaccines.